221 related articles for article (PubMed ID: 35949766)
1. Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
Elsayed M; Harry S; Nanua S; Zaidi S; Habib MH; Raza S
Cureus; 2022 Jul; 14(7):e26619. PubMed ID: 35949766
[TBL] [Abstract][Full Text] [Related]
2. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N; Orazi A; Tefferi A
Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
[TBL] [Abstract][Full Text] [Related]
3. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
4. A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant
Gao T; Yu C; Xia S; Liang T; Gu X; Liu Z
Ther Adv Hematol; 2020; 11():2040620720927105. PubMed ID: 32782768
[TBL] [Abstract][Full Text] [Related]
5. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
6. Current and evolving understanding of atypical chronic myeloid leukemia.
Schwartz LC; Mascarenhas J
Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms.
Sadigh S; Hasserjian RP; Hobbs G
Curr Opin Hematol; 2020 Mar; 27(2):122-127. PubMed ID: 31904665
[TBL] [Abstract][Full Text] [Related]
8. Atypical Chronic Myeloid Leukemia: Where Are We Now?
Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
[TBL] [Abstract][Full Text] [Related]
9. Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia.
Khanna V; Pierce ST; Dao KH; Tognon CE; Hunt DE; Junio B; Tyner JW; Druker BJ
Cureus; 2015 Dec; 7(12):e414. PubMed ID: 26870618
[TBL] [Abstract][Full Text] [Related]
10. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
11. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
Kim SY; Song IC; Kim J; Kwon GC
Ann Diagn Pathol; 2024 Apr; 71():152317. PubMed ID: 38642470
[TBL] [Abstract][Full Text] [Related]
12. Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment.
Castellino A; Santambrogio E; Rapezzi D; Massaia M
Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684141
[TBL] [Abstract][Full Text] [Related]
13. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
14. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract][Full Text] [Related]
16. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A; Kasprzak A; Germing U
Front Oncol; 2021; 11():778741. PubMed ID: 34869027
[TBL] [Abstract][Full Text] [Related]
17. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
Fend F; Horn T; Koch I; Vela T; Orazi A
Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
[TBL] [Abstract][Full Text] [Related]
18. Atypical CML with TET2 mutation, associated with NRAS and KRAS: A case report and literature review.
Abuzneid YS; Alzeerelhouseini HIA; Marzouqa N; Yaghi Y; Al-Ihribat AR; Alqam B; Krama A
Ann Med Surg (Lond); 2021 Nov; 71():102980. PubMed ID: 34840744
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
[TBL] [Abstract][Full Text] [Related]
20. Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report.
Yamamoto M; Suzuki S; Mukae JI; Tanaka K; Watanabe K; Oshikawa G; Fukuda T; Murakami N; Miura O
Oncol Lett; 2017 Sep; 14(3):3717-3721. PubMed ID: 28927137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]